Safety first: pIOL is effective for myopic astigmatism

Article

Implantation of the Artiflex toric iris-fixated phakic IOL is effective, predictable and safe for the correction of myopic astigmatism.

Implantation of the Artiflex toric iris-fixated phakic IOL is effective, predictable and safe for the correction of myopic astigmatism, claims a study in the Journal of Cataract and Refractive Surgery.

Dr Gonzalo Muñoz et al., Refractive Surgery Department, Marqués de Sotelo Ophthalmic Clinic, Barcelona, Spain, conducted a cohort study on 42 eyes of 25 patients age 21 to 39 years.

Refraction, uncorrected (UDVA) and corrected (CDVA) distance visual acuities, complications, pIOL misalignment, and endothelial cell count (ECC) were evaluated 12 months postoperatively. Vector analysis was used to calculate indices of success and misalignment.

Mean spherical equivalent was reduced from −8.85 D ± 2.71 SD to −0.37 ± 0.46 D, with 66.7% of the eyes within ±0.50 D. Mean cylinder power reduced from−2.90 D to −0.39 D. A UDVA of 0.5 or better was achieved in all eyes, along with a CDVA of 0.8 or better.

Mean clinical pIOL misalignment was 2.6 ± 1.8 degrees and one eye required surgical repositioning of the pIOL. Mean ECC reduction was 9.3% ± 1.8%, with iris pigment precipitates observed in 16.7% of eyes. Vector analysis demonstrated excellent mean indices of success for overall, spherical and astigmatic corrections.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.